19 results about "Phosphonatase" patented technology

Featured are polypeptides that include soluble alkaline phosphatases, mutants, fragments, fusion proteins thereof, and methods of use thereof, for treating bone mineralization disorders, such as hypophosphatasia (HPP), and symptoms thereof. The polypeptides include a soluble alkaline phosphatase (sALP) or fragment thereof, which is derived from a naturally occurring alkaline phosphatase (ALP).

Featured are polypeptides that include soluble alkaline phosphatases, mutants, fragments, fusion proteins thereof, and methods of use thereof, for treating bone mineralization disorders, such as hypophosphatasia (HPP), and symptoms thereof. The polypeptides include a soluble alkaline phosphatase (sALP) or fragment thereof, which is derived from a naturally occurring alkaline phosphatase (ALP).

The present disclosure relates generally to processes for providing compounds that can be used as inhibitors of ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1), which inhibitors can be useful in treating or preventing soft bone diseases, such as hypophosphatasia (HPP).

Provided herein are methods for treating hypophosphoesterase (HPP), the methods comprising administering a therapeutically effective amount of an inhibitor of exonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1).

The invention relates to a method for synthesizing D-psicose through polyphosphate-driven high-temperature-resistant multienzyme catalysis, belongs to the technical field of synthetic biology, and solves the problem of low space-time conversion rate during production of D-psicose. According to the method, D-glucose is taken as a substrate, a crude enzyme is constructed through recombinant escherichia coli, and then an in-vitro multi-enzyme one-pot reaction is adopted to prepare the D-glucose. The recombinant escherichia coli is used for respectively carrying out overexpression on polyphosphate glucokinase, 6-phosphate glucose isomerase, D-psicose-6-phosphoric acid-3 epimerase and D-psicose-6-phosphoric acid-phosphatase. The recombinant escherichia coli is used for respectively carrying out overexpression on the polyphosphate glucokinase, the 6-phosphate glucose isomerase, the D-psicose-6-phosphoric acid-phosphatase. After the crude enzyme is prepared, the reuse effect of the immobilized enzyme is better. A multi-enzyme system in the invention is heat-resistant enzyme, and polyphosphate is added as enzyme power supply. According to the method, the space time yield of synthesizing D-psicose from D-glucose is increased, and ATP is not added externally. The method is simple in preparation process, high in product space-time conversion rate, short in catalytic synthesis time, green, economical and suitable for industrial production.

The present disclosure features methods for treating neutralizing antibodies that reduce the efficacy of soluble alkaline phosphatase therapy (e.g., asfoenzyme alpha), which is an enzyme replacement therapy, such as for the treatment of bone mineralization disorders, e.g., hypophosphoesterase (HPP). The methods include diagnosing the subject for the presence of a neutralizing antibody that affects the efficacy of the treatment, administering a treatment suitable for reducing the deleterious effects of the neutralizing antibody, and continuing an alkaline phosphatase treatment.

The application discloses a coumarin tyramine glycoside compound and application thereof in preparation of PTP1B inhibitors and anti-diabetic drugs, and a structural formula of the compound is shown in the following formula: wherein R represents a fatty (aromatic) acyl or a monosaccharide substituent, and R' represents a hydrogen atom or an acetyl group; the compound is prepared by taking 4-methoxycoumarin tyramine 4'-acetyl-O-L-rhamnose as a starting material, introducing a fatty (aromatic) acyl or a monosaccharide substituent into a 2-position hydroxyl and a 3-position hydroxyl of L-rhamnose at the same time, and then removing a protecting group of a sugar group. Pharmacological activity tests show that the compound has good inhibitory activity on protein tyrosine phosphatase 1B, and it is indicated that the coumarin tyramine glycoside compound can be researched and utilized as a new type of PTP1B inhibitor and anti-diabetic drug.

Provided herein are circular, non-integrating, non-viral DNA vectors which express a TNALP polypeptide in an improved expression cassette, wherein the DNA vectors are capable of forming one or more specialized secondary structures, for example an extended cruciform structure, and methods of using such DNA vectors. These DNA vectors having improved expression cassettes provide for increased potency and long-term TNALP transgene expression.

The present invention discloses an oleanane-type triazole glycoside compound and its application in the preparation of PTP1B inhibitors and anti-diabetic drugs. The structural formula of the compound is: wherein R represents a saccharide group, which is oleanolic acid C 28 The oleanane-type triazole glycoside is prepared by converting the 3-hydroxyl group of methyl n-aminohexanoate into a 4-pentynyl ester as the starting material, followed by a click reaction with an azidosugar compound to introduce different sugar units. Pharmacological activity tests have shown that the oleanane-type triazole glycoside has excellent inhibitory activity against protein tyrosine phosphatase 1B and can be studied and utilized as a novel PTP1B inhibitor and antidiabetic drug.

The invention discloses mycobacterium bacteriophage bactericidal protein and a preparation method thereof. The preparation method comprises the following steps: S1, constructing a bacteriophage gene gp48 induced expression strain; s2, determining a phage gene expression strain; s3, constructing a phage metallophosphatase induced expression strain; s4, purifying the phage metal phosphatase protein; according to the invention, a metal phosphoesterase is identified in a bacteriophage genome with relatively strong lysis activity on mycobacterium tuberculosis and mycobacterium smegmatis, and the expression of the metal phosphoesterase has relatively strong killing activity on bacteria and relatively strong phosphodiesterase activity in vitro; the invention also provides a safe and convenient protein preparation method of the phage metal phosphatase.

Provided herein are circular, non-integrating, non-viral DNA vectors which express a TNALP polypeptide in an improved expression cassette, wherein the DNA vectors are capable of forming one or more specialized secondary structures, for example an extended cruciform structure, and methods of using such DNA vectors. These DNA vectors having improved expression cassettes provide for increased potency and long-term TNALP transgene expression.

The invention relates to an application of a carboline compound separated from marine organisms, in particular to an application of the compound in preparation of a protein tyrosine phosphatase PTP1B inhibitor and a pharmaceutical preparation for treating type 2 diabetes. The compound can be used as a PTP1B inhibitor for treating type 2 diabetes mellitus.

The invention discloses an alkaline phosphatase response type near-infrared fluorescent probe and a preparation method and application thereof, the fluorescent probe is a compound XDM-P, the molecular structure of the fluorescent probe comprises a donor-pi-conjugate-receptor type near-infrared fluorophore constructed by taking xanthene and cyanoisophorone as parent nucleuses, and a recognition group linked by a phosphate bond; the preparation method comprises Knoevenagel condensation, phosphorylation and selective dealkylation reaction. The probe is subjected to specific hydrolysis under the action of alkaline phosphatase (ALP), the intramolecular charge transfer effect is recovered, and near-infrared fluorescence 'OFF-ON' response at 774 nm is realized. The probe provided by the invention has high sensitivity, good linear response and deep tissue penetrating ability, and can be used for intracellular ALP detection and non-invasive, real-time and semi-quantitative in-vivo fluorescence imaging of liver cancer tumor-bearing mouse and drug-induced liver injury mouse models.

A method for treating hypophosphatasia (HPP) is provided herein, comprising administering a therapeutically effective dose of an ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1) inhibitor. A method for using an ENPP1 inhibitor to treat or prevent cartilage disease is disclosed herein. In some embodiments, the cartilage disease is hypophosphatasia. Ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1) is an extracellular enzyme that hydrolyzes ATP to PPi and AMP in the extracellular space.

The present invention provides gene therapy plasmids and transgenes comprising soluble tissue non-specific alkaline phosphatase, recombinant virus vectors for delivery of said viral plasmids and transgenes and medical uses relating to the treatment of pyrophosphate deposition diseases and / or hypophosphatasia.

The application discloses a reference gene of Irpex lacteus, primers and application thereof. The reference gene comprises ubiquitin conjugating enzyme 1, autophagy protein Atg8, ubiquitin conjugating enzyme 2, calmodulin-dependent phosphatase and fungal protein kinase gene. The five reference genes disclosed in the application are suitable for expression level research of different expression level genes. The reference gene provided by the application has stable expression in different development periods and different culture conditions, and the reference primers have high specificity, stable amplification and amplification efficiency close to 100%. In addition, according to the expression level of a target gene, a suitable reference gene can be selected from the five reference genes for expression level research. The application provides new candidate reference genes which are more stable and more extensive than common reference genes such as gapdh for gene expression research of Irpex lacteus.

The present disclosure provides methods and compositions for culturing, engineering, and administering engineered B lineage cell populations that produce an ALP or a fusion protein thereof, such as ALP-Fc fusion protein comprising alkaline phosphatase and human immunoglobulin fragment crystallizable region.

The present application belongs to the technical field of medical material preparation, and particularly relates to a dentin sensitivity desensitizer based on chitosan self-assembly and enzymatic mineralization technology and a preparation method thereof. The amorphous chitosan core-based desensitizer of the present application can not only deeply penetrate into dentin tubules, but also realize rapid mineralization through the loaded phosphatase. Compared with traditional dentin sensitivity desensitizers, the amorphous chitosan desensitizer of the present application has rapid effect and good blocking effect. The results of the examples show that the dentin sensitivity desensitizer provided by the present application can fully and effectively penetrate into the dentin tubules, can form a dense mineralized layer on the surface and inside of the dentin tubules, and the blocking depth exceeds 200 mu m.